Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, CA 94945, USA.
Mol Neurodegener. 2013 Oct 27;8:42. doi: 10.1186/1750-1326-8-42.
Spinocerebellar ataxia type 7 (SCA7) is caused by a toxic polyglutamine (polyQ) expansion in the N-terminus of the protein ataxin-7. Ataxin-7 has a known function in the histone acetylase complex, Spt/Ada/Gcn5 acetylase (STAGA) chromatin-remodeling complex. We hypothesized that some histone deacetylase (HDAC) family members would impact the posttranslational modification of normal and expanded ataxin-7 and possibly modulate ataxin-7 function or neurotoxicity associated with the polyQ expansion. Interestingly, when we coexpressed each HDAC family member in the presence of ataxin-7 we found that HDAC3 increased the posttranslational modification of normal and expanded ataxin-7. Specifically, HDAC3 stabilized ataxin-7 and increased modification of the protein. Further, HDAC3 physically interacts with ataxin-7. The physical interaction of HDAC3 with normal and polyQ-expanded ataxin-7 affects the toxicity in a polyQ-dependent manner. We detect robust HDAC3 expression in neurons and glia in the cerebellum and an increase in the levels of HDAC3 in SCA7 mice. Consistent with this we found altered lysine acetylation levels and deacetylase activity in the brains of SCA7 transgenic mice. This study implicates HDAC3 and ataxin-7 interaction as a target for therapeutic intervention in SCA7, adding to a growing list of neurodegenerative diseases that may be treated by HDAC inhibitors.
脊髓小脑共济失调 7 型(SCA7)是由蛋白 ataxin-7 的 N 端的毒性聚谷氨酰胺(polyQ)扩展引起的。Ataxin-7 在组蛋白乙酰转移酶复合物 Spt/Ada/Gcn5 乙酰转移酶(STAGA)染色质重塑复合物中具有已知的功能。我们假设某些组蛋白去乙酰化酶(HDAC)家族成员会影响正常和扩展的 ataxin-7 的翻译后修饰,并可能调节与 polyQ 扩展相关的 ataxin-7 功能或神经毒性。有趣的是,当我们在存在 ataxin-7 的情况下共表达每个 HDAC 家族成员时,我们发现 HDAC3 增加了正常和扩展的 ataxin-7 的翻译后修饰。具体而言,HDAC3 稳定了 ataxin-7 并增加了蛋白质的修饰。此外,HDAC3 与 ataxin-7 发生物理相互作用。HDAC3 与正常和 polyQ 扩展的 ataxin-7 的物理相互作用以 polyQ 依赖性方式影响毒性。我们在小脑的神经元和神经胶质中检测到大量的 HDAC3 表达,并在 SCA7 小鼠中发现 HDAC3 水平增加。与这一致的是,我们在 SCA7 转基因小鼠的大脑中发现了赖氨酸乙酰化水平和脱乙酰酶活性的改变。这项研究表明,HDAC3 和 ataxin-7 的相互作用是 SCA7 治疗干预的靶点,这增加了可能通过 HDAC 抑制剂治疗的神经退行性疾病的数量。